Patient-reported outcomes and safety in adolescent and adult atopic dermatitis patients treated with dupilumab: real-world insights one year into the globostad multinational prospective observational study

Dédée F. Murrell¹, Silvia M. Ferrucci², Caterina Foti³, Bibiana Perez-Garcia⁴, Hilde Lapeere⁵, Piergiacomo Calzavara-Pinton⁶, Anne-Claire Fougerousse⁷,⁸, Jiangming Wu⁹, Marius Ardeleanu¹⁰, Kwinten Bosman¹¹

¹St George Hospital, University of New South Wales, Sydney, NSW, Australia; ²Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ³University of Bari "Aldo Moro", Bari, Italy; ⁴Ramón y Cajal University Hospital, Madrid, Spain; ⁵Ghent University Hospital, Ghent, Belgium; ⁶University of Brescia, Brescia, Italy; ⁷Military Teaching Hospital Begin, Saint Mandé, France; ⁸ResoEczéma, Paris, France; ⁹Sanofi, Bridgewater, NJ, USA; ¹⁰Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA; ¹¹Sanofi, Amsterdam, Netherlands

**Introduction:** The GLOBOSTAD study aims to capture long-term dupilumab effectiveness in real-world atopic dermatitis (AD) treatment.

**Objective:** To present patient-reported outcomes, that complement clinical AD assessments and guide healthcare decision-making, and a summary of adverse events one year after dupilumab initiation.

**Methods:** The GLOBOSTAD five-year, multinational, prospective, observational study (NCT03992417) enrolled patients aged ≥12 years with moderate-to-severe AD. Patients received dupilumab based on country-specific prescribing information. Assessments were performed at baseline, 3 months (M; ±1M), 6M (±2M), and 12M (±2M). Data are reported as observed for enrollment/safety (N = 955; data cutoff: March 2023) and follow-up (N = 903) populations.

**Results:** 758/863/705 patients completed ≥1 follow-up assessment at 3M/6M/12M, respectively. During the study, patients reported rapid improvements in mean (SD) patient-oriented eczema measure from
19.7 (6.4) at baseline to 8.7 (6.6) at 3M to 7.1 (5.8) at end of observation period (12M); pruritus numerical rating scale from 6.3 (2.2) to 2.5 (2.4) to 1.7 (2.0); scoring of atopic dermatitis sleep loss score from 5.6 (3.0) to 1.7 (2.3) to 1.0 (1.8); dermatology life quality index (DLQI) from 13.7 (7.1) to 5.3 (5.1) to 3.9 (4.2); and children’s DLQI from 12.2 (6.2) to 2.7 (2.9) to 4.8 (4.8). Adverse events considered related to dupilumab by the investigator were reported in 187 (19.6%) patients. Adverse events leading to permanent dupilumab discontinuation were reported in 23 (2.4%) patients.

**Conclusion:** On initiating dupilumab treatment, patients reported rapid improvements in skin lesions, itch, sleep, and overall quality of life, from severe/very large effect scores to mild/small effect scores, which were sustained for up to one year. Safety data were consistent with previous studies.

**Keywords:** Real-world evidence, dupilumab, atopic dermatitis, patient-reported outcomes.

**Acknowledgments and Funding Sources:**

Data first presented at the 2024 American Academy of Dermatology Association (AAD) Meeting; San Diego CA, March 8-12, 2024. Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc. ClinicalTrials.gov Identifier: NCT03992417. Medical writing/editorial assistance was provided by Sumitra Debina Mitra, PhD of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice guidelines.

**Disclosures:**

**Murrell DF:** Argenx, AstraZeneca, Principia Biopharma, Regeneron Pharmaceuticals Inc., Roche – investigator; Argenx, Principia Biopharma, Regeneron Pharmaceuticals Inc., Roche – advisory board; co-creator of BPDAI. **Ferrucci SM:** AbbVie, Almirall, Amgen, Bayer, Eli Lilly, Galderma, LEO Pharma, Novartis, Sanofi – principal investigator; Novartis – advisory board member; Almirall, Menarini, Novartis – honoraria for lectures and research grants. **Foti C:** Abbvie, Sanofi – speaker. **Perez-Garcia B:** AbbVie,
Boehringer Ingelheim, Faes Farma, Galderma, LEO Pharma, Lilly, Meda Pharmaceuticals, Pierre Fabre, Sanofi – speaker/consultant fees. **Lapeere H:** AbbVie, Eli Lilly, LEO Pharma, Pfizer, Sanofi – advisory board member. **Calzavara-Pinton P:** AbbVie, Almirall, Cantabria Labs, Celgene, Galderma, Janssen, LEO Pharma, Meda Pharmaceuticals, Sanofi – advisory board member. **Fougerousse A-C:** AbbVie, LEO Pharma, Lilly, Pfizer, Sanofi – consultant. **Wu J, Bosman K:** Sanofi – employees, may hold stock and/or stock options in the company. **Ardeleanu M:** Regeneron Pharmaceuticals Inc. – employee and shareholder